Stay updated with breaking news from Agonist Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist...
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and...
08.08.2022 - – Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of patients with ALSP – – Prioritizing VGL101 in ALSP and small molecule TREM2 agonist programs; ...
08.08.2022 - - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) - Celldex ...